Diana Spencer speaks to Dr Muhunthan Thillai, CEO at Qureight, about the company’s AI-powered imaging analytics and the technology’s potential in lung diseases and beyond.  DS: Can you provide some background to the company? MT: We are a core imaging laboratory using deep-learning and analytics to advance clinical trials and we are based in Cambridge […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!